Heron Therapeutics | HRTX - Loan Capital


Heron Therapeutics reported $140.64M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
ALKERMES USD 1.48B 1.2B Mar/2026
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
ANI Pharmaceuticals USD 286M 5.84M Mar/2026
Arrowhead Research USD 1.23B 687.3M Mar/2026
Eisai JPY 134.78B 12M Mar/2026
Emergent BioSolutions USD 446.5M 1.7M Dec/2023
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Insmed USD 542.22M 1.25M Mar/2026
Ligand Pharmaceuticals USD 446.19M 702K Dec/2025
Merck USD 46.67B 77M Mar/2026
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Omeros USD 403.72M 27.2M Jun/2024
Pacira USD 367.66M 4.53M Mar/2026
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Roche Holding CHF 27.43B 966M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Veracyte USD 0 0 Mar/2025
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025